Detail akcie Celldex Theraptc Rg online

Business Summary: Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Company’s bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Celldex Therapeutics, Inc. revenues increased from $2.4M to $6.9M. Net loss increased 26% to $141.4M. Revenues reflect Contracts and Grants increase from $2.3M to $6.6M, Revenue Sales of Goods & Services increase from $56K to $278K. Higher net loss reflects Research and Development increase of 43% to $106.1M (expense), Gain on Fair Value Remeasurement of Cont decrease from $6.9M (income) to $0K.